VIDEO: Richard Stefanacci, DO, Addresses Cost Concerns of Neurodegenerative Diseases
Richard Stefanacci, DO, Associate Professor, Health Policy & Public Health, University of the Sciences, says there are 2 cost concerns associated with neurodegenerative diseases. One is the actual cost of the disease and the second is the cost of diagnostic testing. Dr Stefanacci also says that treatments are now currently inexpensive, but with new emerging therapiess the costs will rise.
This video was taken on Thursday, November 8 at the NAMCP Fall Forum in Las Vegas, NV.
As patents on some of the most lucrative medicines began to expire, many companies shifted money to rare-disease drugs, knowing that those medicines cost less to develop and will face limited competition.
The ENABLE trial, conducted in rural regions of Vermont and New Hampshire, reports a positive impact on the 1-year survival of advanced cancer patients. A parallel study, ENABLE III, reported benefits to caregivers following early introduction of palliative care in these advanced cancer patients.